Press release content from Business Wire. The AP news staff was not involved in its creation.
Agilent Receives Approval for GenetiSure Dx Postnatal Assay in Japan
December 23, 2020 GMT
SANTA CLARA, Calif. (BUSINESS WIRE) Dec 22, 2020
Agilent Technologies Inc. (NYSE: A) announced it has obtained clearance from the Ministry of Health, Labour and Welfare (MHLW) in Japan for the GenetiSure Dx Postnatal Assay – a microarray-based assay for diagnostic use. This assay enables clinical geneticists to detect genetic aberrations associated with developmental delay, intellectual disabilities, congenital anomalies, and unexplained dysmorphic features. The company also announced that it has registered its microarray scanner, SureScan Dx Scanner, as a Class I medical device in Japan, intended for use with the assay.